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Background: The essential oil from Fructus Alpiniae zerumbet (FAZ) is its principal bioactive ingredient, and is
widely used in Miao folk herbs in Guizhou province for the treatment of gastrointestinal and cardiovascular
diseases. Several studies have confirmed that FAZ ameliorates hyperlipidemia and atherosclerosis. Because
endothelial dysfunction often accompanies cardiovascular diseases, especially hyperlipidemia and atherosclerosis,
the present study concentrated on evaluating the endothelial protective effects of the essential oil from FAZ
(EOFAZ) on oxidized low-density lipoprotein (ox-LDL)-induced injury of cultured human umbilical vein endothelial
cells (HUVECs) and on the regulation of oxidative stress.
Methods: Cell viability was analyzed with the MTT assay and trypan blue exclusion staining (TBES). Cell injury was
assessed by lactate dehydrogenase (LDH) release. Biochemical enzymatic methods were used to evaluate the
oxidative stress, including the lipid peroxidation product, malondialdehyde (MDA), reduced glutathione (GSH),
superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px).
Results: The redox status of HUVECs was significantly exacerbated after exposure to ox-LDL. EOFAZ protected
HUVECs against ox-LDL injury as assessed by the MTT assay, TBES and LDH release. Furthermore, EOFAZ ameliorated
the oxidative stress by elevating the activities of SOD, CAT and GSH-Px, and increasing the GSH levels, in addition
to attenuating the MDA contents.
Conclusions: The present data provide the first experimental evidence that EOFAZ protects endothelial cells
against ox-LDL-induced injury, and indicate that this protection involves ameliorating the redox status.
Keywords: Essential oil, Fructus Alpiniae zerumbet, Human umbilical vein endothelial cells, Oxidized low-density
lipoprotein, Oxidative stressBackground
It is well known that atherosclerosis (AS) is the leading
cause of death in most Western countries, and is a cru-
cial pathological factor in the development of cardiovas-
cular diseases, leading to alterations and lesions in the
inner walls of blood vessels [1]. Endothelial cells are cru-
cial for maintaining the physiological functions of the
cardiovascular system, and endothelial dysfunction has* Correspondence: shenxiangchun@126.com
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reproduction in any medium, provided the orbeen implicated in the initiation and propagation of AS
processes [2]. Increasing evidence suggests that stress by
an imbalanced cellular activity of production and elimi-
nation of reactive oxygen species (ROS) is involved in
the pathophysiology of AS [3]. Although its etiology is
multifactorial, endothelial dysfunctions, especially those
elicited by oxidized low-density lipoproteins (ox-LDL),
play a critical role in the pathogenesis of AS. ox-LDL
promotes vascular dysfunction by exerting cytotoxicity
directly on endothelial cells and by enhancing the produc-
tion of inflammatory mediators, including ROS, proinflam-
matory cytokines and arachidonic acid metabolites [4].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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peutic strategy against AS.
The Zingiberaceae is a large diverse family comprising
1,200 species belonging to 49 genera. A prominent
member of this family is the Alpinia genus. Plants of this
genus are used in herbal medicine all over the world.
Alpinia zerumbet, also known as Alpinia speciosa or
Alpinia nutans [5], is an aromatic perennial ginger herb
originating in the East Indies and naturalized in the sub-
tropical and tropical regions of South America, Oceania
and Asia [6]. In phytotherapy, A. zerumbet has been
shown to possess pharmacological activities, including as
an antioxidant and in the treatment of various condi-
tions such as intestinal disorders, hypertension and in-
flammation [7,8].
In China, A. zerumbet is named Yanshanjiang, and has
been used as a very valuable herbal medicine for hun-
dreds of years. The herbalists used to separate each part
of the A. zerumbet plant and apply them separately to
different therapeutic uses. In particular as local Miao
folk herbs in Guizhou province, the fruit was widely
used against cardiovascular diseases. The essential oil
from Fructus A. zerumbet (EOFAZ) has been shown to
have major medicinal effects involving anti-inflamma-
tion, protection against cardiovascular diseases and anti-
hypertension, as well as antioxidant activity [9,10]. Also,
our previous research confirmed that the EOFAZ vasore-
laxant effects depend on the endothelium-intact [11]. In
another study we showed that compared to that of the
fruit, the composition of the essential oil from the leaves
is significantly different [12]. It is well known that ox-
LDL-induced endothelial cell injury is a key pathological
process in atherosclerosis. Considering all these aspects,
especially the EOFAZ endothelium ameliorating func-
tion and the antiatherosclerosis effect, the present study
was undertaken to evaluate the amelioration of the cel-
lular redox status by EOFAZ for prevention of ox-LDL-
induced endothelial cell injury.
Methods
Chemical and herbal materials
The essential oil was extracted from the fruit of A.
zerumbet, which was collected in Zhenfeng county,
Guizhou province, China, in October 2009. The fruit
was identified by Professor Chen Zu-yun, and a voucher
specimen (No.20091026) was deposited at the Research
Division of Pharmacology, Guiyang Medical University.
The isolation of the essential oil was carried out at the
school of Pharmacy of the Guiyang Medical University,
according to a method described elsewhere [13]. Briefly,
chopped fruit was placed in a glass flask connected at
one end to a glass vessel with water and at the other end
to a water-cooled condenser. The water was heated to
boiling point, and the steam percolated through thechopped fruit and collected in the condenser. After con-
densation, the watery phase with its solutes, termed the
‘hydrolate’, was separated from the oily phase; the essen-
tial oil when re-diluted in water is termed the ‘pseudo-
hydrolate’. Sixty-two compounds were separated and 58
were identified from the essential oil. The composition
of EOFAZ was determined by gas chromatography and
mass spectrometry: β-phellandrene (16.388%), β-pinene
(15.056%), 1,8-cineole (10.956%), camphene (10.120%),
α-pinene (9.275%), linalool L (4.026%), camphor (3.657%),
O-cymene (3.384%), β-myrcene (3.189%), borneol L
(2.446%), caryophyllene oxide (1.778%) and terpinen-4-ol
(1.756%); over 12 volatile compounds accounted for
82.03% of the total [12]. Pravastatin sodium standard sub-
stance (PRA) was purchased from the National Institute
for the Control of Pharmaceutical and Biological Products
of China, Beijing.
Cell culture and treatments
Cell cultures were carried out essentially as described
previously [14,15], with some modifications. Endothelial
cells were isolated and pooled from human umbilical
cords obtained less than 3 h after delivery (cords were
obtained from three healthy puerperae donors, who gave
informed consent, and the acquisition of tissues was car-
ried out in line with the principles of the Declaration of
Helsinki and all procedures with patients were approved
by the ethical review board of Guiyang Medical Univer-
sity according to local and national guidelines). After
rinsing, the veins were cannulated and incubated with
50 U/ml collagenase (Sigma-Aldrich, St. Louis, MO,
USA) in serum-free M199 medium for 10 min. Primary
cultures were seeded at a concentration of approxi-
mately 4×104 cells/cm2 onto 75-cm2 flasks precoated
with 0.01% (w/v) polygeline in phosphate-buffered saline
(PBS). The culture medium was used M199 with Earle’s
salts (Sigma-Aldrich), containing 20% (v/v) human
serum (Shanghai Hengyuan, Shanghai, China), 5 U/ml
penicillin G, 5 pg/ml streptomycin sulfate and 150 pg/ml
endothelial cell growth supplement (Sigma-Aldrich).
Cells reached confluency within approximately 4 d, and
were cultured at 37°C in a humidified atmosphere with
5% CO2. The medium was changed a day after seeding
and every 2 d thereafter.
For all experiments, cells were used at passages 3 to 6
and seeded at a concentration of 1×105 cells/ml in 96-
well plates, 24-well plates, or six-well plates. Treatments
were carried out on a confluent monolayer of cells.
EOFAZ was freshly prepared as a stock solution in
DMSO and diluted with culture medium. DMSO was
present at an equal concentration (0.02% final concen-
tration) in all groups except for the PRA group. ox-LDL
was used for no more than 2 wk from the date of pro-
duction (Yiyuan Biotechnology, Guangzhou, China).
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before being exposed to 100 mg/L ox-LDL for 24 h ex-
cept for the control group. After treatment, the cells
cultured in the 96-well plates were used for the 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT; Sigma-Aldrich) assay, those in the six-well
plates were used for trypan blue (Beyotime, Haimen,
China) exclusion staining (TBES), and those in the 24-
well plates were assayed for the contents of malondial-
dehyde (MDA), glutathione (GSH) and LDH, and for the
anti-oxidative enzymatic activity of superoxide dismutase
(SOD), catalase (CAT) and glutathione peroxidase
(GSH-Px). All experiments were performed in triplicate
(four or five cultures were used for the experiments),
however, the TBES assay was performed only once, but
on four cultures.
Cell viability measurements by the MTT assay and TBES
Cell viability was measured by the MTT reduction assay
as previously described [16]. Cells from at least six wells
were used for each group. Briefly, after a 24 h exposure
to ox-LDL (100 mg/L), the supernatant was removed
and the cells were gently washed with PBS followed by
80 μl of fresh culture medium and addition of 20 μl
MTT (5 mg/ml). After 4 h of incubation, 200 μl of
DMSO, the solubilization/stop solution, was added to dis-
solve the formazan crystals, and the absorbance was read
by a microplate reader (Sunrise RC, Tecan, Switzerland) at
a wavelength of 570 nm. Inhibition of cell damage (%) was
calculated with the following formula:
Inhibition of cell damage %ð Þ
¼ ODtreated group ODoxLDL group
 
= ODcontrol group ODoxLDL group
 
 100
The TBES method is another classic cell viability
method [17]. HUVECs in six-well plates were pretreated
with EOFAZ or PRA for 30 min and then stimulated
with 100 mg/L ox-LDL for 24 h. Then the cells were
harvested and centrifuged to remove the medium. Cells
were washed three times with PBS and resuspended to
make a suspension of 1×106 cells/ml. The suspension
was mixed with 0.4% trypan blue dye for 5 min at 25°C,
and the unstained (viable) and stained (nonviable) cells
were counted on a hemacytometer within 5 min in
five 40× microscope fields per well.
LDH activity in the medium
To evaluate cell injury, the LDH released from the cyto-
sol into the culture medium was measured as previously
described [18]. After treatment with EOFAZ or PRA,
followed by incubation with 100 mg/L ox-LDL for 24 h,
the medium was collected from each well. Supernatantswere obtained by centrifugation at 12,000×g at 4°C for
10 min. LDH release was determined using an LDH
assay kit according to the manufacturer’s instructions
(Nanjing Jiancheng Co., Nan Jing, China). In brief, 100
μl supernatant, 250 μl buffer and 50 μl coenzyme were
mixed and incubated for 15 min at 37°C, followed by
addition of 250 μl 2,4-dinitrophenylhydrazine and an-
other 15 min incubation at 37°C in the dark. Finally, 2.5
ml NaOH (0.4 mol/L) were added to the reaction mix-
ture. Three minutes later, 200 μl of each reaction mix-
ture were transferred into a new 96-well plate. The
absorbance was read at 440 nm with an ELISA reader.
Cell lysate preparation
HUVECs were pretreated with EOFAZ or PRA for 30
min and then incubated with 100 mg/L ox-LDL for 24 h
in 24-well plates. The cells were lysed with extraction
buffer (20 mM Tris–HCl, pH 7.5, 150 mM NaCl, 1 mM
EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate, 1 mM glycerophosphate, 1 mM Na3VO4,
1 μg/ml leupeptin and 1 mM PMSF). Cell lysates from
each well were collected and used for determination of
MDA and GSH contents and anti-oxidative enzymatic
activity. Protein concentrations of cell extracts were
determined by the BCA assay (Santa Cruz Biotechnolo-
gies, Santa Cruz, CA, USA).
Measurement of malondialdehyde (MDA) and glutathione
(GSH) concentrations
The total levels of MDA, the lipid peroxidation product
in the lysates, were measured by the thiobarbituric acid-
reactive substance (TBARS) assay as described previ-
ously [19]. The lysates (100 μl) were mixed in glass test
tubes with 3 ml of 1% phosphoric acid, 1 ml of 0.67%
thiobarbituric acid and 0.04% butylated hydroxytoluene,
and the mixtures were incubated in a boiling water bath
for 60 min. Marbles were placed on the tops of the tubes
during the incubation period to avoid excessive loss of
reaction mixture. After cooling the tubes in ice, 1.5 ml
of n-butanol were added and the reaction mixture
was centrifuged at 1000×g for 10 min. The absorbance
of the supernatant was read at 535 nm. The concentra-
tions of TBARS were calculated using tetraethoxypro-
pane as a reference standard. Results were expressed in
nmol/mg protein.
Intracellular GSH was measured using the enzymatic
recycling assay [20]. Aliquots (20 μl) were mixed with
100 mM TEA, 600 mM DTNB, and 210 mM NADPH
in 6.3 mM EDTA-0.125 mM NaH2PO4, pH 7.5 buffer.
The final volume was 200 μl and the reaction was
initiated by adding 0.1 units GSH reductase. Absorbance
was read at 405 nm in a 96-well plate format using an
ELX800 microplate reader (Bio Tek, Winooski, VT, USA),
and concentrations were determined using purified GSH
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protein (nmol/mg protein).Table 1 Protective effects of EOFAZ on HUVECs’ injury
induced by ox-LDL
Groups Dose (mg/L) OD570 Inhibition of cellActivity assay of anti-oxidative enzymes
SOD activity was measured by the xanthine/xanthine
oxidase mediated ferricytochrome c reduction assay [21].
One unit of SOD activity was defined as the amount that
reduced the absorbance at 550 nm by 50%. Fifty microli-
ters of lysates were added to 2.9 ml of reaction buffer
(0.5 μmol xanthine, 0.1 mM NaOH and 2 μmol cyto-
chrome c in 50 mM K2HPO4-Na2HPO4/0.1 mM EDTA,
pH 7.8). The reaction was initiated by adding 50 μl of
xanthine oxidase solution (0.2 U/ml in 0.1 mM EDTA).
The absorbance change was monitored for 3 min at
25°C. Activities were calculated using a concurrently run
standard curve and expressed per mg of protein. The
SOD activity results were expressed as U/mg protein.
The GSH-Px activity assay was conducted by quantify-
ing the rate of oxidation of the reduced glutathione
(GSH) to the oxidized glutathione by H2O2, which is cat-
alyzed by GSH-Px. One unit of GSH-Px was defined as
the amount that reduced the level of GSH by 1 μmol/L
in 1 min per mg protein. GSH-Px activity was measured
in a 1.0 ml cuvette containing 400 μl of 0.25 M potas-
sium phosphate buffer (pH 7.0), 200 μl of sample, 100 μl
of 10mM GSH, 100 μl of 2.5 mM NADPH and 100 μl of
glutathione reductase (6 U/ml). Hydrogen peroxide
(100 μl of 12 mM) was then added, and the change in
absorbance was measured at 1min intervals for 5 min at
366 nm [22]. GSH-Px activity was expressed as U/mg
protein compared to the standard.
CAT activity was detected by methods of our lab [23].
Briefly, 2.8 ml of 10 mmol/L H2O2 were added to a 5 ml
cuvette that contained 0.2 ml of 1 mol/L Tris–HCl (pH
8.0) in an ice-water bath, and absorbance was measured
immediately at 240 nm, which was OD0. Then 10 μl of
lysate were added to the cuvette. The mixture was
incubated at 25°C for 4 min, and then absorbance
was measured, which was OD4. For the nonenzymatic
reaction cuvette, the procedure was the same as for
the enzymatic cuvette, but the cell lysate supernatant
was substituted by distilled water, which was ODn. The
results were expressed as catalytic activity following the
equation: U/mg protein = (OD0−OD4−ODn) ×CH2O2/
Cprotein × 4.damage (%)
Control — 1.85±0.11
ox-LDL 100 0.98±0.12# #
ox-LDL+EOFAZ 100+0.1 1.25±0.20** 31.0
100+0.01 1.09±0.25 12.6
ox-LDL+PRA 100+10 μmol/L 1.19±0.21* 24.1
# # p < 0.01, compared with the control group; *p < 0.05 and ** p < 0.01,
compared with the ox-LDL group.Statistical analysis
Data were expressed as mean ± S.E.M (standard error of
the mean) of at least three independent experiments.
The differences in mean values among the experimental
groups were measured using two-tailed analysis of vari-
ance (ANOVA) followed by Dunnett’s test. Differences
were considered statistically significant at p < 0.05.Results
EOFAZ attenuates the MTT reduction and blue staining
ratio of HUVECs induced by ox-LDL
The MTT assay utilizes the yellow MTT, which is metabo-
lized by the mitochondrial succinate dehydrogenase to yield
a purple formazan reaction product. Exposure of endothe-
lial cells to 100 mg/L ox-LDL for 24 h significantly reduced
cell viability (Table 1; 1.85 ± 0.11 in control vs. 0.98 ± 0.12
in 100 mg/L ox-LDL alone, p < 0.01). Preincubation with
0.1 mg/L EOFAZ restored viability significantly, but 0.01
mg/L EOFAZ had no effect (1.25±0.20 and 1.09±0.25 vs.
0.98±0.12, respectively, p<0.01 and p>0.05; Table 1). A simi-
lar protective effect was observed in the PRA treated group.
The potential toxicity of EOFAZ to HUVECs was examined
by addition of EOFAZ at 0.01, 0.1, 1 and 10 mg/L to the ve-
hicle control medium. These concentrations had no effect
on the survival of HUVECs, except for the 10 mg/L that led
to a significant reduction in viability data were not shown.
These results suggest that EOFAZ at concentrations of up
to 1 mg/L is effective and safe to use with HUVECs. The
trypan blue staining exclusion test is widely used to deter-
mine the number of viable cells present in a cell suspension.
After incubation with 100 mg/L ox-LDL for 24 h, the num-
ber of stained cells significantly increased compared with
the control group, and EOFAZ-pretreatment significantly
decreased the cell blue staining ratio (Figure 1).EOFAZ inhibits LDH release from cells treated
with ox-LDL
A 24 h exposure to 100 mg/L ox-LDL resulted in a
marked and significant facilitation of LDH release from
the cells, compared with the vehicle control group (555.15
±59.67 U/L vs. 269.12 ± 97.80 U/L, p < 0.01). In contrast,
the LDH activity in the supernatant was significantly
decreased in the samples pretreated with 0.1 mg/L
EOFAZ compared with the samples treated with ox-LDL
alone (328.68 ± 61.29 U/L vs. 555.15±59.67 U/L, p < 0.01;
Figure 2).
Figure 1 Effects of EOFAZ on trypan blue exclusion staining in HUVECs' injury induced by ox-LDL. HUVECs were pretreated for 30 min
with EOFAZ or PRA, and then exposed to 100 mg/L ox-LDL for 24 h. A cell suspension was mixed with a 0.4% trypan blue dye for 5 min at 25°C,
and the unstained (viable) and stained (nonviable) cells were counted in a hemacytometer. The values shown are mean ± S.E.M. of three
experiments (four or five cultures per experiment). ##p < 0.01, vs. control group; *p < 0.05, **p < 0.01, vs. ox-LDL group.
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contents in cells treated with ox-LDL
In the present study, incubation of HUVECs with 100
mg/L ox-LDL for 24 h resulted in a significant increase
in the MDA contents, which was significantly attenuated
by EOFAZ or PRA pretreatment (Figure 3). However,
the exposure of HUVECs to ox-LDL 100 mg/L for 24 h
resulted in a significant decrease in GSH contents,
which was ameliorated by preincubation with EOFAZ or
PRA (Figure 4).EOFAZ upregulates the activities of antioxidant enzymes
The main scavengers responsible for inactivation and
termination of free oxygen radicals are SOD, CAT, and
the glutathione system. Our results indicated that the ac-
tivities of the anti-oxidative enzymes were significantly
decreased after HUVECs were exposed to 100 mg/L ox-
LDL, and that EOFAZ and PRA improved these activ-
ities (Figures 5, 6 and 7). Preincubation with 0.1 mg/LFigure 2 Effects of EOFAZ on LDH activity in HUVECs' injury induced
the culture medium was collected to examine LDH activity. The values sho
experiment). ##p < 0.01, vs. control group; *p < 0.05, **p < 0.01, vs. ox-LDLEOFAZ significantly ameliorated the activities of SOD,
CAT and GSH-Px in the cell lysates. Preincubation with
0.01 mg/L EOFAZ enhanced the activities of these
enzymes, however, these results were not statistically
significant. PRA (10 μmol/L) alleviated the decreased
activities of SOD and CAT (**p < 0.01, compared
with the ox-LDL treatment), but did not improve the
GSH-Px activity.Discussion
To the best of our knowledge, the present study demon-
strates for the first time that EOFAZ (the composition was
significantly different from previous reports and from the
essential oil extract from the fruit of A. zerumbet) protects
against endothelial cell injury induced by ox-LDL via
ameliorating oxidative stress, which may be the main
underlying mechanism.
Human umbilical vein endothelial cells (HUVECs)
have played a major role as a model system for studyingby ox-LDL. HUVECs were treated as described in Figure 1, and then
wn are mean ± S.E.M. of three experiments (four or five cultures per
group.
Figure 3 Effects of EOFAZ on MDA contents in HUVECs' injury induced by ox-LDL. HUVECs were treated as described in Figure 1, followed
by cell lysate preparation. MDA contents was measured with the thiobarbituric acid-reactive substance (TBARS) assay. The values shown are mean
± S.E.M. of three experiments (four or five cultures per experiment). ##p < 0.01, vs. control group; **p < 0.01, vs. ox-LDL group.
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the endothelium in the response of the blood vessel wall
to stretch, shear forces, and the development of athero-
sclerotic plaques and angiogenesis [24]. It is well known
that the atherosclerotic lesion is characterized by an ac-
cumulation of lipids carried by lipoproteins, such as
low-density lipoprotein (LDL). LDL becomes susceptible
to (non)enzymatic oxidative modifications when retained
in the artery wall [25]. These modifications make LDL a
potent effector of cellular functions. Multiple lines of
evidence suggest that oxidative stress, characterized by
an elevated generation of ROS, is involved in the patho-
genesis of AS, which implies that oxidized-LDL may
promote the development of AS through oxidative
stress, and is one of the most important risk factors for
AS and cardiovascular morbidity [26]. Endothelial dys-
function elicited by ox-LDL has been demonstrated as
the key step in the initiation of AS. It is widely accepted
that ox-LDL-induced endothelial dysfunction is asso-




















Figure 4 Effects of EOFAZ on GSH contents in HUVECs' injury induced
performed as described in Figure 3. The enzymatic recycling assay was use
three experiments (four or five cultures per experiment). ##p < 0.01, vs. conameliorating the redox status has been a key therapeutic
strategy against AS in the clinic [27].
The cell injury was evaluated by the MTT assay, TBES,
and LDH release, which are widely accepted methods
for cell injury evaluation. The MTT assay is a quantita-
tive colorimetric method to determine cell proliferation
or injury. It utilizes the yellow MTT, which is metabo-
lized by the mitochondrial succinate dehydrogenase to
yield a purple formazan reaction product. The TBES
method is widely used to determine the number of vi-
able cells and is based on the principle that live cells
possess intact cell membranes that exclude certain dyes,
such as trypan blue, eosin and propidium, whereas dead
cells do not. Lactate dehydrogenase (LDH) is a stable
enzyme in the cytosol, present in all cell types, that is
rapidly released into the medium upon damage of the
plasma membrane; hence it is a biomarker for cell mem-
brane damage. The cell injury induced by incubation
with ox-LDL for 24 h was confirmed by the MTT assay




by ox-LDL. HUVECs treatment and cell lysate preparation were
d to detect the GSH contents. The values shown are mean ± S.E.M. of
trol group; *p < 0.05, **p < 0.01, vs. ox-LDL group.
Figure 5 Effects of EOFAZ on SOD activity in HUVECs exposed to ox-LDL. HUVECs treatment and cell lysate preparation were performed as
described in Figure 3. SOD activity was measured by the xanthine/xanthime oxidase mediated ferricytochrome c reduction assay. The values
shown are mean ± S.E.M. of three experiments (four or five cultures per experiment). ##p < 0.01, vs. control group; **p < 0.01, vs. ox-LDL group.
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EOFAZ or PRA ameliorated the cell injury.
Membranes of bioplasm are very rich in polyunsatu-
rated fatty acids, which are especially sensitive to free
radical-induced lipid peroxidation. In oxidative stress,
superoxide anion and hydrogen peroxide are formed and
cannot be readily scavenged because of the low activities
of CAT, SOD and GSH-Px in the endothelial cell [28].
Augmentation of endogenous antioxidants (SOD, CAT
and GSH-Px) has been recognized as an important
pharmacological property present in natural as well as
many synthetic compounds [29]. This constitutes a
major mechanism of protection against oxidative stress
[30,31]. The most abundant ROS generated in living sys-
tems is the superoxide radical, which is acted upon by
SOD to produce hydrogen peroxide, which in turn is
broken down by catalase and/or GSH-Px into water and
oxygen. Thus, increase in both SOD and catalase along
with GSH-Px activity is considered to be more beneficial
in the event of oxidative stress.Figure 6 Effects of EOFAZ on CAT activity in HUVECs exposed to ox-L
described in Figure 3. CAT activity was assayed as described in the Method
(four or five cultures per experiment). ##p < 0.01, vs. control group; **p < 0Exposure to 100 mg/L ox-LDL for 24 h, increased the
MDA contents, decreased the GSH contents, and inhib-
ited the enzymes’ antioxidant activity, indicating that the
redox status was exacerbated. In the present study, a 30
min preincubation with EOFAZ significantly elevated the
activities of SOD, CAT and GSH-Px, whereas PRA only
enhanced the activity of SOD and CAT. Obviously,
EOFAZ scavenged hydrogen peroxide and superoxide
anion, further decreasing the formation of hydroxyl radi-
cals and attenuating lipid peroxidative damage after the
HUVECs were exposed to ox-LDL. However, it is not clear
whether EOFAZ induces the expression of the
endogenous antioxidant enzymes or whether it has direct
protective effects of endogenous antioxidants. PRA, a
hydroxymethylglutaryl-CoA reductase inhibitor, is a mem-
ber of the statins drug class and was used here as a posi-
tive control. PRA, which is used for lowering cholesterol
and preventing cardiovascular disease, and is widely used
to prevent AS, has anti-oxidative effects [32]. The present
results confirmed previous research.DL. HUVECs treatment and cell lysate preparation were performed as
s section. The values shown are mean ± S.E.M. of three experiments
.01, vs. ox-LDL group.
Figure 7 Effects of EOFAZ on GSH-Px activity in HUVECs exposed to ox-LDL. HUVECs treatment and cell lysate preparation were performed
as described in Figure 3. GSH-Px activity was determined by quantifying the rate of oxidation of the reduced glutathione (GSH) to the oxidized
glutathione (GSSG) by H2O2, which is catalyzed by GSH-Px. The values shown are mean ± S.E.M. of three experiments (four or five cultures per
experiment). ##p < 0.01, vs. control group; *p < 0.05, vs. ox-LDL group.
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inactivation of endothelial cells by increasing permeabil-
ity and as potent inducers of endothelial cell death. The
level of MDA reflects the extent of cell damage by oxi-
dative stress [33]. GSH is an intracellular reductant that
plays major roles in catalysis, metabolism and transport,
and protects cells against free radicals, peroxides, and
other toxic compounds, as it is a critical factor involved
in the glutathione system to scavenge hydrogen peroxide
and organic hydroperoxides [34]. It is well known that a
deficiency in GSH within living organisms can lead to
tissue disorders and injury. The present study demon-
strated that EOFAZ alleviated the increase in MDA and
the decrease in GSH contents caused by the ox-LDL-
induced endothelial cell damage, suggesting it has the
potential to protect the membranes of HUVECs from
lipid peroxidative damage.
Endothelial dysfunction is an early feature of both ath-
erosclerosis and vascular diseases, which may lead to an
improvement of prognosis in patients with cardiovascu-
lar risk factors preventing the development of athero-
sclerosis and consequently promoting a reduction in
cardiovascular events [35]. Chronic inflammation and
oxidative stress play crucial roles in endothelial dysfunc-
tion and atherosclerosis [36]. Controlling a variety of
risk factors causing inflammation and oxidative stress
with combination therapy may simultaneously address
multiple mechanisms underlying the pathogenesis of
atherosclerosis. EOFAZ has been shown to be an anti-
inflammatory agent in previous research [37] and the
current results confirmed it is also an antioxidant,
which may provide a novel therapy for atherosclerosis in
the clinic.
In summary, the present research indicates that increase
in HUVECs’ lipid peroxidation and depletion of endogen-
ous antioxidants support the occurrence of oxidativestress after exposure to ox-LDL. Furthermore, it was ac-
companied by cell viability decrease, which was confirmed
by the MTT assay, trypan blue exclusion, and LDH re-
lease. EOFAZ protected the cells against oxidative stress,
as evidenced by inhibition of the increased MDA contents
and decreased GSH contents, alleviation of CAT, SOD
and GSH-Px activities, and finally, enhancement of cell
viability. The mechanism of this protection can be attribu-
ted to the augmented endogenous antioxidant reserve in
HUVECs and/or a direct antioxidant effect. This study
shows that EOFAZ from natural products may be an ex-
cellent protecting agent against endothelial cell injury in
the clinic; the mechanism will be explored in detail and a
clinical evaluation conducted in future research.
Conclusions
The present findings provide the first experimental evi-
dence that EOFAZ protects endothelial cells against ox-
LDL-induced injury, and indicate that this protection
involves amelioration of the redox status.
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